Related Experiment Video
Updated: Jul 20, 2025
Porous Silicon Microparticles for Delivery of siRNA Therapeutics
Published on: January 15, 2015
Advances with Lipid-Based Nanosystems for siRNA Delivery to Breast Cancers
Md Abdus Subhan1,2, Nina Filipczak3, Vladimir P Torchilin3,4
1Department of Chemistry, ShahJalal University of Science and Technology, Sylhet 3114, Bangladesh.
Abstract:
Breast cancer is the most frequently diagnosed cancer among women. Breast cancer is also the key reason for worldwide cancer-related deaths among women. The application of small interfering RNA (siRNA)-based drugs to combat breast cancer requires effective gene silencing in tumor cells. To overcome the challenges of drug delivery to tumors, various nanosystems for siRNA delivery, including lipid-based nanoparticles that protect siRNA from degradation for delivery to cancer cells have been developed. These nanosystems have shown great potential for efficient and targeted siRNA delivery to breast cancer cells. Lipid-based nanosystems remain promising as siRNA drug delivery carriers for effective and safe cancer therapy including breast cancer. Lipid nanoparticles (LNPs) encapsulating siRNA enable efficient and specific silencing of oncogenes in breast tumors. This review discusses a variety of lipid-based nanosystems including cationic lipids, sterols, phospholipids, PEG-lipid conjugates, ionizable liposomes, exosomes for effective siRNA drug delivery to breast tumors, and the clinical translation of lipid-based siRNA nanosystems for solid tumors.
Insights
Lipid nanoparticles effectively deliver small interfering RNA (siRNA) to silence genes in breast cancer cells. This review explores lipid-based nanosystems for targeted siRNA delivery and clinical translation in cancer therapy.
Area of Science:
- Oncology
- Nanotechnology
- Pharmacology
Background:
- Breast cancer is a leading cause of cancer deaths in women globally.
- Effective gene silencing in tumor cells is crucial for breast cancer treatment.
- Challenges in drug delivery necessitate advanced nanosystems for siRNA therapeutics.
Purpose of the Study:
- To review lipid-based nanosystems for small interfering RNA (siRNA) delivery in breast cancer.
- To discuss the potential of these systems for targeted gene silencing in tumors.
- To examine the clinical translation of lipid-based siRNA nanosystems for solid tumors.
Main Methods:
- Review of various lipid-based nanosystems for siRNA delivery.
- Discussion of components like cationic lipids, sterols, phospholipids, and PEG-lipid conjugates.
- Exploration of ionizable liposomes and exosomes as delivery vehicles.
Main Results:
- Lipid nanoparticles (LNPs) demonstrate efficient and specific silencing of oncogenes in breast tumors.
- Nanosystems protect siRNA from degradation and facilitate targeted delivery to cancer cells.
- Lipid-based systems show significant promise for safe and effective breast cancer therapy.
Conclusions:
- Lipid-based nanosystems are highly promising for siRNA drug delivery in breast cancer.
- These advanced systems offer potential for targeted gene silencing and improved therapeutic outcomes.
- Further clinical translation of lipid-based siRNA nanosystems is anticipated for solid tumor treatment.
More Related Videos
09:09Preparation of Neutrally-charged, pH-responsive Polymeric Nanoparticles for Cytosolic siRNA Delivery
Published on: May 2, 2019
15:55Long-term Silencing of Intersectin-1s in Mouse Lungs by Repeated Delivery of a Specific siRNA via Cationic Liposomes. Evaluation of Knockdown Effects by Electron Microscopy
Published on: June 21, 2013
Related Concept Videos
02:30siRNA - Small Interfering RNAs
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
02:30Small interfering RNAs (siRNA)
02:15Experimental RNAi